5亿元仲裁款付清，振东制药与朗迪公司纠纷落幕

Core Viewpoint - The contract dispute between Shanxi Zhendong Pharmaceutical Co., Ltd. and Beijing Landi Pharmaceutical Co., Ltd. has been resolved, with Zhendong Pharmaceutical paying a total of 500 million yuan in arbitration fees, concluding nearly a year of contention [1][2][3]. Group 1: Arbitration Resolution - Zhendong Pharmaceutical has completed the payment of 500 million yuan as per the arbitration ruling, with the final payment of 100 million yuan made on July 18 [3]. - The arbitration was initiated by Landi Pharmaceutical, which sought 1.467 billion yuan in compensation from Zhendong Pharmaceutical [2]. - The arbitration case was officially concluded on January 24, 2025, with both parties bearing their respective legal and arbitration costs [2]. Group 2: Financial Performance - Zhendong Pharmaceutical has reported continuous losses for three consecutive years, with revenues declining from 37.29 billion yuan in 2022 to 29.71 billion yuan in 2024, representing year-on-year decreases of 26.80%, 2.75%, and 18.06% respectively [4]. - The net profit attributable to shareholders has also seen significant declines, with losses of approximately 512.9 million yuan, 439.84 million yuan, and 1.329 billion yuan for the years 2022, 2023, and 2024, reflecting year-on-year declines of 101.96%, 14.24%, and 2920.55% respectively [4]. - The substantial drop in performance in 2024 was attributed to non-operational factors such as major arbitration issues, overdue trust products, and inventory impairments [4]. Group 3: Core Product Performance - The decline in revenue is linked to struggles in core products amid intense market competition [6]. - Zhendong Pharmaceutical's key products include the patented compound Qushi injection and the Minoxidil lotion, with the latter being a significant focus for the company [7]. - The market share of the Minoxidil lotion reached 47.3%, but the company does not hold the patent for this product, indicating a need for time to improve overall performance [7].